目的 探討膽舒膠囊聯(lián)合復(fù)方阿嗪米特治療慢性膽囊炎的臨床療效。方法 回顧性分析2016年2月—2017年2月在廣州市第十二人民醫(yī)院進(jìn)行治療的90例慢性膽囊炎患者的臨床資料，所有患者應(yīng)用隨機(jī)數(shù)字表隨機(jī)分為對照組（45例）和治療組（45例）。對照組口服復(fù)方阿嗪米特腸溶片，2片/次，3次/d；治療組在對照組的基礎(chǔ)上口服膽舒膠囊，2粒/次，3次/d；兩組均連續(xù)治療4周。觀察兩組患者臨床療效，同時比較治療前后兩組患者臨床癥狀積分、血清細(xì)胞因子水平變化。結(jié)果 治療后，對照組和治療組的總有效率分別為80.00%、95.56%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P< 0.05）。兩組的臨床癥狀評分均顯著降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P< 0.05）；且治療組這些臨床癥狀積分明顯低于對照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P< 0.05）。兩組血清白細(xì)胞介素-6（IL-6）、腫瘤壞死因子-α（TNF-α）、β內(nèi)啡肽（β-EP）水平均顯著降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P< 0.05）；且治療組這些血清細(xì)胞因子水平明顯低于對照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P< 0.05）。結(jié)論 膽舒膠囊聯(lián)合復(fù)方阿嗪米特腸溶片治療慢性膽囊炎不僅能夠顯著改善臨床癥狀，而且還可降低機(jī)體炎癥反應(yīng)，具有一定的臨床推廣應(yīng)用價值。

Objective To investigate the clinical effect of Danshu Capsules combined with Compound Azimtamide Entieric-coated Tablets in treatment of chronic cholecystitis. Methods The clinical data of patients (90 cases) with chronic cholecystitis in Guangzhou 12th People's Hospital from February 2016 to February 2017 were retrospectively analyzed. Patients were divided into control (45 cases) and treatment (45 cases) groups by random number table. Patients in the control group were po administered with Compound Azimtamide Entieric-coated Tablets, two tablets/time, three times daily. Patients in the treatment group were po administered with Danshu Capsules on the basis of the control group, two grains/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and clinical symptom scores and serum cytokine levels in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 80.00% and 95.56%, respectively, and there was difference between two groups (P < 0.05). After treatment, the clinical symptom scores in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the clinical symptom scores in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, IL-6, TNF-α, and β-EP in two groups significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the serum cytokine levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Danshu Capsules combined with Compound Azimtamide Entieric-coated Tablets in treatment of chronic cholecystitis can not only significantly improve the clinical symptoms, but also reduce the body's inflammatory response, which has a certain clinical application value.